Such sensitivity is better than the recently identified autoantibody biomarkers in early-stage ESCC reported by our team, including autoantibodies against ezrin, fascin, and L1CAM [23, 34, 35], which indicates that autoantibodies against STIP1 might be an encouraging candidate for establishment of an optimized autoantibody signature required to gain high sensitivity necessary for ESCC screening. The gene discussed is L1CAM; the disease is esophageal squamous cell carcinoma.